Canaccord Genuity Maintains Buy on TELA Bio, Lowers Price Target to $2
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Caitlin Roberts maintains TELA Bio (NASDAQ:TELA) with a Buy and lowers the price target from $4 to $2.
Canaccord Genuity analyst Caitlin Roberts maintains TELA Bio (NASDAQ:TELA) with a Buy and lowers the price target from $4 to $2.